New drug combo shows promise for tough cancers
NCT ID NCT04514497
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to find the safest dose and see if the combination is tolerable. About 29 participants are enrolled, and the study is no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BAY 1895344 (elimursertib) combined with irinotecan or topotecan
- What this could lead to
- If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapy.
- What could go wrong
- This is a very early (Phase 1) trial with only 29 participants, so safety and dosing are still being figured out. The drug combination may cause serious side effects or may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Siteman Cancer Center at Christian Hospital
St Louis, Missouri, 63136, United States
-
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376, United States
-
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141, United States
-
Siteman Cancer Center-South County
St Louis, Missouri, 63129, United States
-
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut, 06611, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
-
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154, United States
-
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, 64116, United States
-
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, 66210, United States
-
University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas, 66211, United States
-
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Yale University
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?